Israel drugmaker Teva vows to fight US price-fixing lawsuit

Israeli pharmaceutical giant Teva faces charges of price-fixing in a US lawsuit
Israeli pharmaceutical giant Teva faces charges of price-fixing in a US lawsuit

Israeli pharmaceutical giant Teva vowed Saturday to defend itself after being accused of orchestrating price-fixing among drugmakers in a US antitrust lawsuit.

According to The Washington Post, 40 American states joined forces Friday to sue more than a dozen former and current executives of generic drugmakers.

"That the biggest generic drug manufacturer in the world is one of the leaders of this marketwide collusion is beyond disappointing," Connecticut state attorney general William Tong told the Post.

"Teva had understandings with its highest quality competitors to lead and follow each other's , and did so with great frequency and success," the complaint charges, "resulting in many billions of dollars of harm to the over a period of several years."

The lawsuit alleges that companies agreed on prices rather than competing, effectively raising the cost of over 100 drugs.

A spokeswoman for Teva in Israel dismissed the as nothing other than "claims".

"Teva will continue to examine the issue internally and there is nothing in its conduct that could lead to civilian or criminal accountability," she said in a statement sent to AFP.

"Teva supplies high quality medication to patients around the world while retaining its commitment to all laws and rules," she said.

"We will continue to resolutely defend the company."

Last year, the Israeli justice ministry fined Teva $22 million for bribing foreign officials to win business in Russia, Ukraine and Mexico, rather than pressing charges in court against the drugmaker.


Explore further

Israeli drugmaker Teva fined $519 mn in US for foreign bribes

© 2019 AFP

Citation: Israel drugmaker Teva vows to fight US price-fixing lawsuit (2019, May 11) retrieved 20 June 2019 from https://medicalxpress.com/news/2019-05-israel-drugmaker-teva-vows-price-fixing.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more